Fate Therapeutics, Inc. (FATE) earnings
FATE earnings moved a median of -3.25% by the close. Quarterly and annual FATE reports and results, each read against the price at its own news timestamp. Back to the FATE overview →
26 measured FATE earnings events.
Where these FATE earnings landedvs 24 measured FATE earnings reactions
| Middle 50% of FATE earnings reactions | -9.17% to +5.97% |
|---|---|
| Median reaction (to close) | -3.25% |
| Measured reactions | 24 |
Point-in-time · zero look-ahead
Half of the 24 FATE earnings events with a measured close landed between -9.17% and +5.97%; 33% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences | Press release | -0.21% | -2.95% | |
| Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates | Press release | -1.41% | -10.95% | |
| Form 10-Q FATE THERAPEUTICS INC For: Jun 30 | SEC filing · Form 10-Q | -1.41% | -10.95% | |
| Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences | Press release | -1.33% | -3.63% | |
| Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates | Press release | -2.51% | -2.51% | |
| Form 10-Q FATE THERAPEUTICS INC For: Mar 31 | SEC filing · Form 10-Q | -2.51% | -2.51% | |
| Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences | Press release | +0.42% | +6.72% | |
| Form 10-K FATE THERAPEUTICS INC For: Dec 31 | SEC filing · Form 10-K | -2.14% | +6.85% | |
| Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates | Press release | +0.00% | — | |
| Form 10-Q FATE THERAPEUTICS INC For: Sep 30 | SEC filing · Form 10-Q | +0.00% | — | |
| Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates | Press release | +5.26% | +18.95% | |
| Form 10-Q FATE THERAPEUTICS INC For: Jun 30 | SEC filing · Form 10-Q | +5.26% | +18.95% | |
| Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates | Press release | +0.00% | -8.57% | |
| Form 10-Q FATE THERAPEUTICS INC For: Mar 31 | SEC filing · Form 10-Q | +0.00% | -8.57% | |
| Form 10-K FATE THERAPEUTICS INC For: Dec 31 | SEC filing · Form 10-K | -1.10% | +14.29% | |
| Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates | Press release | -0.59% | -11.43% | |
| Form 10-Q FATE THERAPEUTICS INC For: Sep 30 | SEC filing · Form 10-Q | -0.59% | -11.43% | |
| Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates | Press release | +2.66% | -3.25% | |
| Form 10-Q FATE THERAPEUTICS INC For: Jun 30 | SEC filing · Form 10-Q | +2.66% | -3.25% | |
| Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates | Press release | -1.95% | +5.97% | |
| Form 10-Q FATE THERAPEUTICS INC For: Mar 31 | SEC filing · Form 10-Q | -1.95% | +5.97% | |
| Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates | Press release | +1.47% | +3.43% | |
| Form 10-K FATE THERAPEUTICS INC For: Dec 31 | SEC filing · Form 10-K | +2.71% | -3.62% | |
| Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates | Press release | +5.40% | -11.25% | |
| Form 10-Q FATE THERAPEUTICS INC For: Sep 30 | SEC filing · Form 10-Q | +5.40% | -11.25% | |
| Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results | Press release | -4.10% | -7.69% |
Keep exploring
More FATE: analyst actions → · SEC filings → · FATE overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Accuray Incorporated (ARAY) | 288 | 0.00% | 51% |
| Chemed Corp (CHE) | 288 | +0.02% | 53% |
| RenovaCare, Inc. (RCAR) | 286 | 0.00% | 41% |
| Cellectis S.A. - American Depositary Shares (CLLS) | 285 | -0.01% | 37% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.